首页> 外国专利> Expedient and method in order to appraise Shaun's heart inter- Venn in the patient who has contracted a disease in the stable type crown artery characteristic heart disease on the basis of GDF 15 risk

Expedient and method in order to appraise Shaun's heart inter- Venn in the patient who has contracted a disease in the stable type crown artery characteristic heart disease on the basis of GDF 15 risk

机译:基于GDF 15风险评估稳定型冠状动脉特征性心脏病的患者中评估肖恩心脏干预的方法和方法

摘要

As for this invention, Shaun dermal heart inter- Venn in the suffering body which has contracted a disease in the stable type crown artery characteristic heart disease (PCI) being the method of diagnosing the presence of success, the said method, with measurement of the quantity of GDF-15 in the first sample of the said suffering body which is obtained after PCI, and the measuring fixed quantity of its GDF-15 and the reference quantity of GDF-15 which is measured in the second sample of the said patient who to the stable type crown artery characteristic heart disease which is obtained before PCI has contracted a disease it is due to the comparison, diagnosis of presence of the success of PCI is included, in the aforementioned methodIt regards. Furthermore as for this invention, Shaun dermal heart inter- Venn in the suffering body which has contracted a disease in the stable type crown artery characteristic heart disease (PCI), GDF-15 for manufacturing the composition for diagnosis in order to diagnose the presence of success, desirably sodium diuresis peptide and/or it regards the use of expedient in order to measure the quantity of myocardial toroponin. In addition as for this invention, Shaun dermal heart inter- Venn in the suffering body which has contracted a disease in the stable type crown artery characteristic heart disease (PCI) also the device and the kit which are adopted in order to diagnose the presence of success include. Selective figure It is not
机译:关于本发明,作为诊断成功与否的方法,上述方法是通过在稳定型冠状动脉特征性心脏病(PCI)中患病的患病体中的肖恩真皮心脏介入而测定的。在PCI后获得的所述患病体的第一样品中的GDF-15的量,以及在所述患者的第二样品中测量的其GDF-15的测量固定量和GDF-15的参考量对于因PCI而患病之前获得的稳定型冠状动脉特征性心脏病,由于比较,在上述方法中包括对PCI成功与否的诊断。此外,对于本发明,在患有稳定型冠状动脉特征性心脏病(PCI)的疾病的患病体中的肖恩真皮心脏内毒素,GDF-15,用于制造诊断用组合物,以诊断是否存在冠状动脉性心脏病。为了获得成功,理想的是利尿钠肽和/或考虑使用权宜之计来测量心肌素的数量。另外,对于本发明,在稳定型冠状动脉特征性心脏病(PCI)中患了疾病的受苦者体内的肖恩·皮内特尔·韦恩还采用了用于诊断是否存在冠状动脉疾病的装置和套件。成功包括。<选择性图>不是

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号